S Singapore Immunology Network.

If this proves to be safe in humans, it’s rather a major breakthrough for the dengue vaccine field. Associate Professor Leo Yee Sin, Clinical Director of Communicable Diseases Centre and Institute of Infectious Disease and Epidemiology at Tan Tock Seng Medical center who heads the Singapore STOP Dengue Translational and Clinical Research Program said, We are into the seventh decade of dengue vaccine advancement, this indeed can be an thrilling breakthrough that brings us a stage closer to an effective vaccine. Acting Executive Director of Indication, Associate Professor Laurent Renia said, Dengue is a major public health issue in many of the tropical countries. We are very delighted that our collaborative attempts with co-workers in Singapore and China have made a promising stage towards a cost-effective and safe dengue vaccine to combat the growing risk of dengue worldwide.Patients Patients were eligible to participate in the two trials if they were 40 years of age or older and had received a analysis of idiopathic pulmonary fibrosis within the previous 5 years. Extra eligibility criteria were an FVC that was 50 percent or more of the predicted value, a diffusion capability of the lung for carbon monoxide that was 30 to 79 percent of the predicted worth, and high-resolution computed tomography of the upper body performed within the prior 12 months. HRCT images and lung-biopsy specimens were examined centrally by an individual radiologist and an individual pathologist to verify eligibility according to the protocol.